Chroma Medicine Presents Data Demonstrating Near-Complete, Durable In Vivo Silencing with Targeted Epigenetic Editors at 2023 ASGCT Annual Meeting

/PRNewswire/ -- Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced in vivo data...

Related Keywords

Boston ,Massachusetts ,United States ,Aaron Jaffe ,Sahar Abubucker ,Vic Myer ,Angelo Lombardo ,Chroma Medicine Inc ,Head Of Research ,American Society Of Gene Cell Therapy ,American Society ,Cell Therapy ,Annual Meeting ,Targeted Epigenetic Editor ,Near Complete In Vivo Silencing ,Senior Vice President ,Gene Targeting ,Gene Correction ,Senior Director ,Epigenome Editing ,Chroma Medicine ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Biotechnology ,